Suppl. Figure 2 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma

IFN-� ELISpot raw data to validate antigen immunogenicity in patients of origin. Antigens with a significant increased immunogenicity (grey bars and asterisks) or 1.3-fold increased levels of immune responses (grey bars) were further validated in a bigger study sample of healthy individuals and lower-grade glioma patients. Solid line represents mean background of negative control (IgG1). (*, p < 0.05; **, p < 0.01; ***, p < 0.001)